Coya Therapeutics, Inc. (COYA) — 8-K Filings

8-K Filings (18)

• Coya Therapeutics Files 8-K: Officer/Director Changes & Compensation — Apr 2, 2026 Risk: medium
  Coya Therapeutics, Inc. filed an 8-K on April 2, 2026, reporting changes in officers and directors, and compensatory arrangements. The filing includes exhibits
• 8-K Filing — Dec 17, 2025
• Coya Therapeutics Files 8-K: Material Agreement & Equity Sales — Oct 27, 2025 Risk: medium
  Coya Therapeutics, Inc. announced on October 23, 2025, the entry into a material definitive agreement. The company also disclosed unregistered sales of equity s
• Coya Therapeutics Files 8-K Report — Sep 2, 2025 Risk: medium
  On August 29, 2025, Coya Therapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Event' occurred on this date, but the specific details of this e
• Coya Therapeutics Files 8-K on Financials and Operations — Aug 12, 2025 Risk: medium
  Coya Therapeutics, Inc. filed an 8-K on August 12, 2025, reporting on its Results of Operations and Financial Condition, and providing Regulation FD Disclosure.
• Coya Therapeutics Files 8-K — Jul 29, 2025 Risk: low
  Coya Therapeutics, Inc. filed an 8-K on July 29, 2025, to report other events. The filing does not contain specific details about the nature of these events, do
• Coya Therapeutics Files 8-K Report — Jul 1, 2025 Risk: low
  On June 30, 2025, Coya Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. The company's principal ex
• Coya Therapeutics Files 8-K on Shareholder Votes — Jun 26, 2025 Risk: low
  Coya Therapeutics, Inc. filed an 8-K on June 26, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific de
• Coya Therapeutics Appoints New Director, Discloses Officer Compensation — Nov 5, 2024 Risk: medium
  Coya Therapeutics, Inc. announced on November 1, 2024, a change in its board of directors. Specifically, Dr. Michael J. Ybarra has been appointed as a new direc
• Coya Therapeutics Appoints New Director — Oct 31, 2024 Risk: low
  Coya Therapeutics, Inc. announced on October 28, 2024, a change in its board of directors. Specifically, Dr. Jonathan M. Roth was appointed as a Class II Direct
• Coya Therapeutics Files 8-K — Oct 29, 2024 Risk: low
  Coya Therapeutics, Inc. filed an 8-K on October 29, 2024, to report on Regulation FD disclosures and financial statements. The filing does not contain specific
• Coya Therapeutics Files 8-K: Material Agreement & Equity Sales — Oct 22, 2024 Risk: medium
  On October 21, 2024, Coya Therapeutics, Inc. entered into a material definitive agreement. The company also disclosed unregistered sales of equity securities an
• Coya Therapeutics Relocates Principal Executive Offices — Aug 19, 2024 Risk: low
  Coya Therapeutics, Inc. announced on August 16, 2024, a change in its principal executive offices to 5850 San Felipe St., Suite 500, Houston, Texas 77057. This
• Coya Therapeutics Appoints New CEO — Jul 15, 2024 Risk: medium
  On July 12, 2024, Coya Therapeutics, Inc. announced the appointment of Dr. David J. Ebersole as its new Chief Executive Officer, succeeding Dr. Amir Mohammadi.
• Coya Therapeutics Enters Material Definitive Agreement — Jun 5, 2024 Risk: medium
  Coya Therapeutics, Inc. announced on June 4, 2024, that it entered into a Material Definitive Agreement. The filing does not disclose the specific details of th
• Coya Therapeutics Files 8-K: Material Agreement & Equity Sales — May 20, 2024 Risk: medium
  On May 17, 2024, Coya Therapeutics, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company
• Coya Therapeutics Files 8-K: Director, Officer, and Compensation Updates — May 8, 2024 Risk: medium
  Coya Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includ
• Coya Therapeutics Updates Business Address in Houston — Jan 19, 2024
  Coya Therapeutics, Inc. filed an 8-K on January 19, 2024, to update its business address from 12645 Memorial Dr., Suite F1 #305, Houston, TX 77024 to 5850 San F

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX